Ironwood Pharmaceuticals Inc (IRWD) - Total Liabilities
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has total liabilities worth $660.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Ironwood Pharmaceuticals Inc to assess how effectively this company generates cash.
Ironwood Pharmaceuticals Inc - Total Liabilities Trend (2007–2024)
This chart illustrates how Ironwood Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check IRWD financial resilience to evaluate the company's liquid asset resilience ratio.
Ironwood Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
China | CN¥496.16 Million |
|
Chong Hong Construction Co Ltd
TW:5534
|
Taiwan | NT$27.20 Billion |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
China | CN¥816.85 Million |
|
Sercomm Corp
TW:5388
|
Taiwan | NT$32.39 Billion |
|
Changshu Automotive Trim Co
SHG:603035
|
China | CN¥6.34 Billion |
|
CFM Indosuez Wealth SA
PA:MLCFM
|
France | €5.26 Billion |
|
Zhejiang Yingfeng Technology Co Ltd
SHG:605055
|
China | CN¥1.76 Billion |
|
Ackerstein Group Ltd
TA:ACKR
|
Israel | ILA659.66 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Ironwood Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Ironwood Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ironwood Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ironwood Pharmaceuticals Inc (2007–2024)
The table below shows the annual total liabilities of Ironwood Pharmaceuticals Inc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $652.24 Million | -20.20% |
| 2023-12-31 | $817.37 Million | +82.39% |
| 2022-12-31 | $448.14 Million | -13.99% |
| 2021-12-31 | $521.02 Million | +4.92% |
| 2020-12-31 | $496.60 Million | +0.12% |
| 2019-12-31 | $496.00 Million | -6.14% |
| 2018-12-31 | $528.42 Million | -11.31% |
| 2017-12-31 | $595.83 Million | -7.35% |
| 2016-12-31 | $643.11 Million | +22.73% |
| 2015-12-31 | $524.00 Million | +113.91% |
| 2014-12-31 | $244.96 Million | +1.75% |
| 2013-12-31 | $240.74 Million | +180.40% |
| 2012-12-31 | $85.86 Million | -13.38% |
| 2011-12-31 | $99.12 Million | -30.10% |
| 2010-12-31 | $141.81 Million | -69.22% |
| 2009-12-31 | $460.79 Million | +24.16% |
| 2008-12-31 | $371.13 Million | +18.09% |
| 2007-12-31 | $314.28 Million | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as wel… Read more